European equities traded in the US as American depositary receipts were relatively flat late Thursday morning, nudging 0.07% higher to 1,461.21 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by internet browser company Opera (OPRA) and biopharmaceutical company Grifols (GRFS), which climbed 16% and 11%, respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and biotech firm Evaxion Biotech (EVAX), which rose 4.2% and 1.9%, respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Cellectis (CLLS), which lost 3.7% and 2.3%, respectively. They were followed by biopharmaceutical company Genfit (GNFT) and petroleum refiner Equinor (EQNR), which were down 1.8% each.
From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm (TCBP) and Akari Therapeutics (AKTX), which rose 4.4% and 1.7%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which were up 1.2% and 1%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company NuCana (NCNA), which dropped 5.8% and 4.7%, respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Verona Pharma (VRNA), which fell 4.2% and 1.8%, respectively.
Comments